Obesity-related hormones and endometrial cancer among postmenopausal women: A nested case-control study within the B∼FIT cohort

Endocrine-Related Cancer

Volumn 20, Issue 1, 2013, Pages 151-160

  Dallal, Cher M ^a   Brinton, Louise A ^a   Bauer, Douglas C ^b   Buist, Diana M S ^c   Cauley, Jane A ^d   Hue, Trisha F ^b   La Croix, Andrea ^e   Tice, Jeffrey A ^b   Chia, Victoria M ^a,i   Falk, Roni ^a   Pfeiffer, Ruth ^a   Pollak, Michael ^f   Veenstra, Timothy D ^g   Xu, Xia ^g   Lacey, James V ^h  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MCGILL UNIVERSITY   (Canada)

^g FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

Adiponectin; Endometrial cancer; Leptin; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C PEPTIDE; ESTRADIOL; LEPTIN;

AGE; AGED; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

EID: 84874051116     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0229     Document Type: Article

References (33)

1. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K et al. 1999 Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 257 79-83. (doi:10.1006/bbrc. 1999.0255)
2. Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K & Tanaka K 2010 Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecologic Oncology 119 65-69. (doi:10.1016/j.ygyno.2010.07. 007)
3. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D & Cummings SR 1993 Design of the Fracture Intervention Trial. Osteoporosis International 3 (Suppl 3) S29-S39. (doi:10.1007/BF01623005)
4. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 1535-1541. (doi:10.1016/S0140-6736(96)07088-2)
5. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L et al. 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Journal of the American Medical Association 296 2927-2938. (doi:10.1001/jama.296.24.2927)
6. Calle EE & Kaaks R 2004 Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews. Cancer 4 579-591. (doi:10.1038/nrc1408)
7. Cleary MP, Ray A, Rogozina OP, Dogan S & Grossmann ME 2009 Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention. Frontiers in Bioscience: a Journal and Virtual Library 1 329-357.
8. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Journal of the American Medical Association 280 2077-2082. (doi:10.1001/jama.280.24.2077)
9. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, Rinaldi S, Dossus L, Slimani N, Lundin E et al. 2007 Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. Journal of Clinical Endocrinology and Metabolism 92 255-263. (doi:10.1210/jc.2006-1371)
10. Cymbaluk A, Chudecka-Glaz A & Rzepka-Gorska I 2008 Leptin levels in serum depending on body mass index in patients with endometrial hyperplasia and cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology 136 74-77. (doi:10.1016/j.ejogrb.2006.08.012)
11. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS & La Vecchia C 2004 Circulating adiponectin and endometrial cancer risk. Journal of Clinical Endocrinology and Metabolism 89 1160-1163. (doi:10.1210/jc.2003-031716)
12. Fantuzzi G 2005 Adipose tissue, adipokines, and inflammation. Journal of Allergy and Clinical Immunology 115 911-919 (quiz 920). (doi:10.1016/ j.jaci.2005.02.023)
13. Friedman JM & Halaas JL 1998 Leptin and the regulation of body weight in mammals. Nature 395 763-770. (doi:10.1038/27376)
14. Garofalo C & Surmacz E 2006 Leptin and cancer. Journal of Cellular Physiology 207 12-22. (doi:10.1002/jcp.20472)
15. Inoue M, Maehata E, Yano M, Taniyama M & Suzuki S 2005 Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism 54 281-286. (doi:10.1016/j.metabol. 2004.09.006)
16. Kaaks R, Lukanova A & Kurzer MS 2002 Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiology, Biomarkers & Prevention 11 1531-1543.
17. Kaplan RC,HoGY, Xue X, Rajpathak S,Cushman M, Rohan TE, Strickler HD, Scherer PE & Anastos K 2007 Within-individual stability of obesityrelated biomarkers among women. Cancer Epidemiology, Biomarkers & Prevention 16 1291-1293. (doi:10.1158/1055-9965.EPI-06-1089)
18. van Kruijsdijk RC, van der Wall E & Visseren FL 2009 Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiology, Biomarkers & Prevention 18 2569-2578. (doi:10.1158/1055-9965.EPI-09-0372)
19. Lihn AS, Pedersen SB & Richelsen B 2005 Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews 6 13-21. (doi:10.1111/j.1467-789X.2005.00159.x)
20. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, Krogh V, Lenner P, Shore RE, Biessy C et al. 2004a Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. International Journal of Cancer 108 425-432. (doi:10.1002/ijc.11529)
21. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Biessy C et al. 2004b Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. International Journal of Cancer 108 262-268. (doi:10.1002/ijc.11544)
22. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH et al. 2004 Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. Journal of Biological Chemistry 279 12152-12162. (doi:10.1074/jbc.M311113200)
23. Paracchini V, Pedotti P & Taioli E 2005 Genetics of leptin and obesity: a HuGE review. American Journal of Epidemiology 162 101-114. (doi:10.1093/aje/kwi174)
24. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E & Trichopoulos D 2002 Leptin and body mass index in relation to endometrial cancer risk. Annals of Nutrition and Metabolism 46 147-151. (doi:10.1159/000063081)
25. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G & Trichopoulos D 2003 Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. Journal of Clinical Endocrinology and Metabolism 88 993-997. (doi:10.1210/jc.2002-021209)
26. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ et al. 1996 Case-control study of endogenous steroid hormones and endometrial cancer. Journal of the National Cancer Institute 88 1127-1135. (doi:10.1093/jnci/ 88.16.1127)
27. Renehan AG, Roberts DL & Dive C 2008 Obesity and cancer: pathophysiological and biological mechanisms. Archives of Physiology and Biochemistry 114 71-83. (doi:10.1080/13813450801954303)
28. Roberts DL, Dive C & Renehan AG 2010 Biological mechanisms linking obesity and cancer risk: new perspectives. Annual Review of Medicine 61 301-316. (doi:10.1146/annurev.med.080708.082713)
29. Soliman PT,WuD, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM & Lu KH 2006 Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 106 2376-2381. (doi:10.1002/cncr. 21866)
30. Soliman PT, Cui X, Zhang Q, Hankinson SE & Lu KH 2011 Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. American Journal of Obstetrics and Gynecology 167 e161-e165. (doi:10.1016/j.ajog.2010.08.045)
31. Somasundar P, Yu AK, Vona-Davis L & McFadden DW 2003 Differential effects of leptin on cancer in vitro. Journal of Surgical Research 113 50-55. (doi:10.1016/S0022-4804(03)00166-5)
32. Troisi R, Potischman N, Hoover RN, Siiteri P & Brinton LA 1997 Insulin and endometrial cancer. American Journal of Epidemiology 146 476-482. (doi:10.1093/oxfordjournals.aje.a009301)
33. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD & Ziegler RG 2007 Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Analytical Chemistry 79 7813-7821. (doi:10.1021/ ac070494j)